Bio


Dr. Joy Wu is a board-certified endocrinologist with over 12 years' experience who specializes in treating women and men with osteoporosis and other bone and mineral diseases, including primary hyperparathyroidism, vitamin D deficiency, Paget's disease and fibrous dysplasia. She has a special interest in optimizing skeletal health for those at risk of bone loss from glucocorticoid treatment, cancer therapies, or organ transplant. She works closely with each individual and his/her referring physician to assess fracture risk, and to develop a tailored treatment and monitoring plan.

Dr. Wu directs a broad basic and translational research program that focuses on skeletal development and the bone marrow hematopoietic niche. Her laboratory is currently studying stem cell therapies for bone formation, and the prevention of cancer metastases to bone (joywulab.stanford.edu). She has been honored with awards from the NIH Director’s New Innovator Award, the Endocrine Society, the American Society for Bone and Mineral Research, and the Mary Kay Foundation. Dr. Wu is committed to training the next generation of physician scientists, and serves as Co-Director of the Stanford Internal Medicine Translational Investigator Program.

Clinical Focus


  • Osteoporosis
  • Metabolic Bone Disease
  • Endocrinology
  • Diabetes and Metabolism

Administrative Appointments


  • Co-Director, Translational Investigator Program, Department of Medicine (2015 - Present)

Honors & Awards


  • Marsden Memorial Award in Chemistry, Stanford University (1993)
  • Phi Beta Kappa, Stanford University (1993)
  • Alpha Omega Alpha, Duke University School of Medicine (1997)
  • Endocrine Scholars Award, The Endocrine Society (2006)
  • Young Investigator Award, American Society for Bone and Mineral Research Annual Meeting (2006)
  • Merck Senior Fellow Award, The Endocrine Society (2007)
  • John Haddad Young Investigator Award, Advances in Mineral Metabolism (2008)
  • Claflin Distinguished Scholar Award, Massachusetts General Hospital (2009)
  • Clinical Scientist Program Instructor Development Award, Harvard Stem Cell Institute (2009)
  • NIH Director's New Innovator Award, NIH (2011)
  • Cancer Grant Recipient, The Mary Kay Foundation (2013)

Boards, Advisory Committees, Professional Organizations


  • Leadership Task Force, The Endocrine Society (2015 - 2015)
  • Board of Directors, Advances in Mineral Metabolism (2013 - Present)
  • Membership Enhancement Committee, The American Society for Bone and Mineral Research (2013 - Present)
  • Co-Chair, Trainee & Career Development Core Committee, The Endocrine Society (2007 - 2010)
  • Ex Officio, Council, The Endocrine Society (2006 - 2010)
  • Member, The American Society for Bone and Mineral Research (2005 - Present)
  • Member, The Endocrine Society (2003 - Present)

Professional Education


  • Board Certification: Endocrinology, Diabetes and Metabolism, American Board of Internal Medicine (2006)
  • Fellowship:Massachusetts General Hospital (2006) MA
  • Residency:Brigham and Women's Hospital Harvard Medical School (2003) MA
  • Medical Education:Duke University School of Medicine (2001) NC
  • MD/PhD, Duke University (2001)

Current Research and Scholarly Interests


Osteoporosis, a disease of fragile bones resulting in fractures, will strike 50% of women and 25% of men. As a physician scientist, my laboratory is studying stem cells in the skeleton and bone marrow to develop novel regenerative approaches to increase bone quality and strength. We are also interested in how the skeleton supports hematopoiesis, and how diseases and medications that impact bone may affect blood cell production and cancer metastasis. For more detailed descriptions of ongoing research projects in the lab, visit our website at joywulab.stanford.edu.

Clinical Trials


  • Pilot Trial of Zoledronic Acid to Prevent Bone Loss in Hematopoietic Cell Transplant Recipients Not Recruiting

    Patients who undergo bone marrow transplant for different types of cancer are exposed to many treatments such as steroids and whole body radiation. These treatments make the transplant possible but also make their bones weaker and more prone to fractures which can be a source of significant disability and decreased quality of life for cancer survivors. Our trial will investigate whether giving one dose of Zoledronic acid (a commonly used drug given to preserve bone mass in osteoporosis) before bone marrow transplant can protect from the bone loss caused by the transplant procedures. The investigators are also interested in studying the complex interactions of bone, muscle and fat which are greatly affected after bone marrow transplant.

    Stanford is currently not accepting patients for this trial.

    View full details

2017-18 Courses


Stanford Advisees


Graduate and Fellowship Programs


All Publications


  • Older Men with Anemia Have Increased Fracture Risk Independent of Bone Mineral Density. journal of clinical endocrinology and metabolism Valderrábano, R. J., Lee, J., Lui, L., Hoffman, A. R., Cummings, S. R., Orwoll, E. S., Wu, J. Y. 2017

    Abstract

    Extreme low hemoglobin values have been linked to increased risk of fracture at different sites in a small number of studies. However, careful assessment of a clinically relevant cutoff for anemia and cross sectional and longitudinal bone mineral density (BMD) measures is lacking.To determine whether men with anemia were at increased risk of fracture after accounting for bone density and bone loss.Cross-sectional analysis (at visit 3) and prospective analysis (from baseline to visit 3) in the Osteoporotic Fractures in Men (MrOS), a multi-site longitudinal cohort study.6 communities in the U.S.3632 community-dwelling men (>65 years) in MrOS at baseline (2000-2002) who were able to walk without assistance and did not have a hip replacement or fracture and had complete blood counts (CBCs) at visit 3 (2007-2009).Adjudicated spine and non-spine fractures during a median 7.2 years follow up.Analytic baseline characteristics associated with fractures or anemia (Hgb < 12g/dL) were included into multivariable models. Anemia was associated with increased risk of any (HR 1.67; 95% CI 1.26-2.21) and non-spine (HR 1.70; 95% CI 1.25-2.31) fractures. A model including change in BMD slightly attenuated the association with any (HR 1.60; 95% CI 1.20-2.13) and non-spine fractures (HR 1.57; 95% CI 1.14-2.15). Including absolute BMD did not significantly alter the anemia-fracture association. Anemia was not associated with spine fracture.Community-dwelling older men with anemia had a 57-72% increase in non-spine fracture risk independent of bone density and bone loss over time.

    View details for DOI 10.1210/jc.2017-00266

    View details for PubMedID 28368469

  • Bone Density Loss Is Associated With Blood Cell Counts JOURNAL OF BONE AND MINERAL RESEARCH Valderrabano, R. J., Lui, L., Lee, J., Cummings, S. R., Orwoll, E. S., Hoffman, A. R., Wu, J. Y. 2017; 32 (2): 212-220

    View details for DOI 10.1002/jbmr.3000

    View details for Web of Science ID 000396935300004

  • In vivo rescue of the hematopoietic niche by pluripotent stem cell complementation of defective osteoblast compartments. Stem cells (Dayton, Ohio) Chubb, R., Oh, J., Riley, A. K., Kimura, T., Wu, S. M., Wu, J. Y. 2017

    Abstract

    Bone-forming osteoblasts play critical roles in supporting bone marrow hematopoiesis. Pluripotent stem cells (PSCs), including embryonic stem (ES) cells and induced pluripotent stem (iPS) cells, are capable of differentiating into osteoblasts. To determine the capacity of stem cells needed to rescue aberrant skeletal development and bone marrow hematopoiesis in vivo, we employed a skeletal complementation model. Mice deficient in Runx2, a master transcription factor for osteoblastogenesis, fail to form a mineralized skeleton and bone marrow. Wild-type GFP(+) ES and YFP(+) iPS cells were introduced into Runx2-null blastocyst-stage embryos. We assessed GFP/YFP(+) cell contribution by whole-mount fluorescence and histological analysis and found that the proportion of PSCs in the resulting chimeric embryos is directly correlated with the degree of mineralization in the skull. Moreover, PSC contribution to long bones successfully restored bone marrow hematopoiesis. We validated this finding in a separate model with diphtheria toxin A-mediated ablation of hypertrophic chondrocytes and osteoblasts. Remarkably, chimeric embryos harboring as little as 37.5% wild-type PSCs revealed grossly normal skeletal morphology, suggesting a near-complete rescue of skeletogenesis. In summary, we demonstrate that fractional contribution of PSCs in vivo is sufficient to complement and reconstitute an osteoblast-deficient skeleton and hematopoietic marrow. Further investigation using genetically modified PSCs with conditional loss of gene function in osteoblasts will enable us to address the specific roles of signaling mediators to regulate bone formation and hematopoietic niches in vivo. This article is protected by copyright. All rights reserved.

    View details for DOI 10.1002/stem.2670

    View details for PubMedID 28741855

  • Prevention of breast cancer skeletal metastases with parathyroid hormone. JCI insight Swami, S., Johnson, J., Bettinson, L. A., Kimura, T., Zhu, H., Albertelli, M. A., Johnson, R. W., Wu, J. Y. 2017; 2 (17)

    Abstract

    Advanced breast cancer is frequently associated with skeletal metastases and accelerated bone loss. Recombinant parathyroid hormone [teriparatide, PTH(1-34)] is the first anabolic agent approved in the US for treatment of osteoporosis. While signaling through the PTH receptor in the osteoblast lineage regulates bone marrow hematopoietic niches, the effects of anabolic PTH on the skeletal metastatic niche are unknown. Here, we demonstrate, using orthotopic and intratibial models of 4T1 murine and MDA-MB-231 human breast cancer tumors, that anabolic PTH decreases both tumor engraftment and the incidence of spontaneous skeletal metastasis in mice. Microcomputed tomography and histomorphometric analyses revealed that PTH increases bone volume and reduces tumor engraftment and volume. Transwell migration assays with murine and human breast cancer cells revealed that PTH alters the gene expression profile of the metastatic niche, in particular VCAM-1, to inhibit recruitment of cancer cells. While PTH did not affect growth or migration of the primary tumor, it elicited several changes in the tumor gene expression profile resulting in a less metastatic phenotype. In conclusion, PTH treatment in mice alters the bone microenvironment, resulting in decreased cancer cell engraftment, reduced incidence of metastases, preservation of bone microarchitecture and prolonged survival.

    View details for DOI 10.1172/jci.insight.90874

    View details for PubMedID 28878134

    View details for PubMedCentralID PMC5621896

  • Loss of Gsa in the Postnatal Skeleton Leads to Low Bone Mass and a Blunted Response to Anabolic Parathyroid Hormone Therapy. journal of biological chemistry Sinha, P., Aarnisalo, P., Chubb, R., Poulton, I. J., Guo, J., Nachtrab, G., Kimura, T., Swami, S., Saeed, H., Chen, M., Weinstein, L. S., Schipani, E., Sims, N. A., Kronenberg, H. M., Wu, J. Y. 2016; 291 (4): 1631-1642

    Abstract

    Parathyroid hormone (PTH) is an important regulator of osteoblast function and is the only anabolic therapy currently approved for treatment of osteoporosis. The PTH receptor (PTHR1) is a G protein-coupled receptor that signals via multiple G proteins including Gsα. Mice expressing a constitutively active mutant PTHR1 exhibited a dramatic increase in trabecular bone that was dependent upon expression of Gsα in the osteoblast lineage. Postnatal removal of Gsα in the osteoblast lineage (P-GsαOsxKO mice) yielded markedly reduced trabecular and cortical bone mass. Treatment with anabolic PTH(1-34) (80 μg/kg/day) for 4 weeks failed to increase trabecular bone volume or cortical thickness in male and female P-GsαOsxKO mice. Surprisingly, in both male and female mice, PTH administration significantly increased osteoblast numbers and bone formation rate in both control and P-GsαOsxKO mice. In mice that express a mutated PTHR1 that activates adenylyl cyclase and protein kinase A (PKA) via Gsα but not phospholipase C (PLC) via Gq/11 (D/D mice), PTH significantly enhanced bone formation, indicating that PLC activation is not required for increased bone turnover in response to PTH. Therefore while the anabolic effect of intermittent PTH treatment on trabecular bone volume is blunted by deletion of Gsα in osteoblasts, PTH can stimulate osteoblast differentiation and bone formation. Together these findings suggest that alternative signaling pathways beyond Gsα and Gq/11 act downstream of PTH on osteoblast differentiation.

    View details for DOI 10.1074/jbc.M115.679753

    View details for PubMedID 26598522

  • PTH Signaling in Osteoprogenitors Is Essential for B-Lymphocyte Differentiation and Mobilization. Journal of bone and mineral research Panaroni, C., Fulzele, K., Saini, V., Chubb, R., Pajevic, P. D., Wu, J. Y. 2015; 30 (12): 2273-2286

    Abstract

    Cells of the osteoblast lineage provide critical support for B lymphopoiesis in the bone marrow (BM). Parathyroid hormone (PTH) signaling in osteoblastic cells through its receptor (PPR) is an important regulator of hematopoietic stem cells; however, its role in regulation of B lymphopoiesis is not clear. Here we demonstrate that deletion of PPR in osteoprogenitors results in a significant loss of trabecular and cortical bone. PPR signaling in osteoprogenitors, but not in mature osteoblasts or osteocytes, is critical for B-cell precursor differentiation via IL-7 production. Interestingly, despite a severe reduction in B-cell progenitors in BM, mature B-lymphocytes were increased 3.5-fold in the BM of mice lacking PPR in osteoprogenitors. This retention of mature IgD(+) B cells in the BM was associated with increased expression of vascular cell adhesion molecule 1 (VCAM1) by PPR-deficient osteoprogenitors, and treatment with VCAM1 neutralizing antibody increased mobilization of B lymphocytes from mutant BM. Our results demonstrate that PPR signaling in early osteoblasts is necessary for B-cell differentiation via IL-7 secretion and for B-lymphocyte mobilization via VCAM1. © 2015 American Society for Bone and Mineral Research.

    View details for DOI 10.1002/jbmr.2581

    View details for PubMedID 26191777

  • Wnts produced by Osterix-expressing osteolineage cells regulate their proliferation and differentiation. Proceedings of the National Academy of Sciences of the United States of America Tan, S. H., Senarath-Yapa, K., Chung, M. T., Longaker, M. T., Wu, J. Y., Nusse, R. 2014; 111 (49): E5262-71

    Abstract

    Wnt signaling is a critical regulator of bone development, but the identity and role of the Wnt-producing cells are still unclear. We addressed these questions through in situ hybridization, lineage tracing, and genetic experiments. First, we surveyed the expression of all 19 Wnt genes and Wnt target gene Axin2 in the neonatal mouse bone by in situ hybridization, and demonstrated-to our knowledge for the first time-that Osterix-expressing cells coexpress Wnt and Axin2. To track the behavior and cell fate of Axin2-expressing osteolineage cells, we performed lineage tracing and showed that they sustain bone formation over the long term. Finally, to examine the role of Wnts produced by Osterix-expressing cells, we inhibited Wnt secretion in vivo, and observed inappropriate differentiation, impaired proliferation, and diminished Wnt signaling response. Therefore, Osterix-expressing cells produce their own Wnts that in turn induce Wnt signaling response, thereby regulating their proliferation and differentiation.

    View details for DOI 10.1073/pnas.1420463111

    View details for PubMedID 25422448

  • Loss of G(s)alpha Early in the Osteoblast Lineage Favors Adipogenic Differentiation of Mesenchymal Progenitors and Committed Osteoblast Precursors JOURNAL OF BONE AND MINERAL RESEARCH Sinha, P., Aarnisalo, P., Chubb, R., Ono, N., Fulzele, K., Selig, M., Saeed, H., Chen, M., Weinstein, L. S., Pajevic, P. D., Kronenberg, H. M., Wu, J. Y. 2014; 29 (11): 2414-2426

    View details for DOI 10.1002/jbmr.2270

    View details for Web of Science ID 000344222800011

  • Teriparatide ( PTH1-34) Treatment Increases Peripheral Hematopoietic Stem Cells in Postmenopausal Women JOURNAL OF BONE AND MINERAL RESEARCH Yu, E. W., Kumbhani, R., Siwila-Sackman, E., DeLelys, M., Preffer, F. I., Leder, B. Z., Wu, J. Y. 2014; 29 (6): 1380-1386

    Abstract

    Cells of the osteoblast lineage play an important role in regulating the hematopoietic stem cell (HSC) niche and early B cell development in animal models, perhaps via parathyroid hormone (PTH) dependent mechanisms. There are few human clinical studies investigating this phenomenon. We studied the impact of long-term daily teriparatide (PTH 1-34) treatment on cells of the hematopoietic lineage in postmenopausal women. Twenty-three postmenopausal women at high risk of fracture received teriparatide 20 mcg SC daily for 24 months as part of a prospective longitudinal trial. Whole blood measurements were obtained at baseline, 3, 6, 12, and 18 months. Flow cytometry was performed to identify hematopoietic subpopulations, including HSCs (CD34 + /CD45(moderate); ISHAGE protocol) and early transitional B cells (CD19 + , CD27-, IgD + , CD24[hi], CD38[hi]), CD38[hi]). Serial measurements of spine and hip bone mineral density as well as serum P1NP, osteocalcin, and CTX were also performed. The average age of study subjects was 64 ± 5. We found that teriparatide treatment led to an early increase in circulating HSC number of 40% ± 14% (p = 0.004) by month 3, which persisted to month 18 before returning to near baseline by 24 months. There were no significant changes in transitional B cells or total B cells over the course of the study period. In addition, there were no differences in complete blood count profiles as quantified by standard automated flow cytometry. Interestingly, the peak increase in HSC number was inversely associated with increases in bone markers and spine BMD. Daily teriparatide treatment for osteoporosis increases circulating HSCs by 3 to 6 months in postmenopausal women. This may represent a proliferation of marrow HSCs or increased peripheral HSC mobilization. This clinical study establishes the importance of PTH in the regulation of the HSC niche within humans. © 2014 American Society for Bone and Mineral Research.

    View details for DOI 10.1002/jbmr.2171

    View details for Web of Science ID 000336001500010

    View details for PubMedID 24420643

  • Foxp3(+) regulatory T cells maintain the bone marrow microenvironment for B cell lymphopoiesis NATURE COMMUNICATIONS Pierini, A., Nishikii, H., Baker, J., Kimura, T., Kwon, H., Pan, Y., Chen, Y., Alvarez, M., Strober, W., Velardi, A., Shizuru, J. A., Wu, J. Y., Chiba, S., Negrin, R. S. 2017; 8

    Abstract

    Foxp3(+) regulatory T cells (Treg cells) modulate the immune system and maintain self-tolerance, but whether they affect haematopoiesis or haematopoietic stem cell (HSC)-mediated reconstitution after transplantation is unclear. Here we show that B-cell lymphopoiesis is impaired in Treg-depleted mice, yet this reduced B-cell lymphopoiesis is rescued by adoptive transfer of affected HSCs or bone marrow cells into Treg-competent recipients. B-cell reconstitution is abrogated in both syngeneic and allogeneic transplantation using Treg-depleted mice as recipients. Treg cells can control physiological IL-7 production that is indispensable for normal B-cell lymphopoiesis and is mainly sustained by a subpopulation of ICAM1(+) perivascular stromal cells. Our study demonstrates that Treg cells are important for B-cell differentiation from HSCs by maintaining immunological homoeostasis in the bone marrow microenvironment, both in physiological conditions and after bone marrow transplantation.

    View details for DOI 10.1038/ncomms15068

    View details for Web of Science ID 000400847300001

    View details for PubMedID 28485401

    View details for PubMedCentralID PMC5436085

  • Gs alpha Controls Cortical Bone Quality by Regulating Osteoclast Differentiation via cAMP/PKA and beta-Catenin Pathways SCIENTIFIC REPORTS Ramaswamy, G., Kim, H., Zhang, D., Lounev, V., Wu, J. Y., Choi, Y., Kaplan, F. S., Pignolo, R. J., Shore, E. M. 2017; 7

    Abstract

    Skeletal bone formation and maintenance requires coordinate functions of several cell types, including bone forming osteoblasts and bone resorbing osteoclasts. Gsα, the stimulatory subunit of heterotrimeric G proteins, activates downstream signaling through cAMP and plays important roles in skeletal development by regulating osteoblast differentiation. Here, we demonstrate that Gsα signaling also regulates osteoclast differentiation during bone modeling and remodeling. Gnas, the gene encoding Gsα, is imprinted. Mice with paternal allele deletion of Gnas (Gnas(+/p-)) have defects in cortical bone quality and strength during early development (bone modeling) that persist during adult bone remodeling. Reduced bone quality in Gnas(+/p-) mice was associated with increased endosteal osteoclast numbers, with no significant effects on osteoblast number and function. Osteoclast differentiation and resorption activity was enhanced in Gnas(+/p-) cells. During differentiation, Gnas(+/p-) cells showed diminished pCREB, β-catenin and cyclin D1, and enhanced Nfatc1 levels, conditions favoring osteoclastogenesis. Forskolin treatment increased pCREB and rescued osteoclast differentiation in Gnas(+/p-) by reducing Nfatc1 levels. Cortical bone of Gnas(+/p-) mice showed elevated expression of Wnt inhibitors sclerostin and Sfrp4 consistent with reduced Wnt/β-catenin signaling. Our data identify a new role for Gsα signaling in maintaining bone quality by regulating osteoclast differentiation and function through cAMP/PKA and Wnt/β-catenin pathways.

    View details for DOI 10.1038/srep45140

    View details for Web of Science ID 000397312300001

    View details for PubMedID 28338087

    View details for PubMedCentralID PMC5364530

  • Parathyroid Hormone Directs Bone Marrow Mesenchymal Cell Fate. Cell metabolism Fan, Y., Hanai, J., Le, P. T., Bi, R., Maridas, D., DeMambro, V., Figueroa, C. A., Kir, S., Zhou, X., Mannstadt, M., Baron, R., Bronson, R. T., Horowitz, M. C., Wu, J. Y., Bilezikian, J. P., Dempster, D. W., Rosen, C. J., Lanske, B. 2017

    Abstract

    Intermittent PTH administration builds bone mass and prevents fractures, but its mechanism of action is unclear. We genetically deleted the PTH/PTHrP receptor (PTH1R) in mesenchymal stem cells using Prx1Cre and found low bone formation, increased bone resorption, and high bone marrow adipose tissue (BMAT). Bone marrow adipocytes traced to Prx1 and expressed classic adipogenic markers and high receptor activator of nuclear factor kappa B ligand (Rankl) expression. RANKL levels were also elevated in bone marrow supernatant and serum, but undetectable in other adipose depots. By cell sorting, Pref1(+)RANKL(+) marrow progenitors were twice as great in mutant versus control marrow. Intermittent PTH administration to control mice reduced BMAT significantly. A similar finding was noted in male osteoporotic patients. Thus, marrow adipocytes exhibit osteogenic and adipogenic characteristics, are uniquely responsive to PTH, and secrete RANKL. These studies reveal an important mechanism for PTH's therapeutic action through its ability to direct mesenchymal cell fate.

    View details for DOI 10.1016/j.cmet.2017.01.001

    View details for PubMedID 28162969

  • Evidence for use of Teriparatide in Spinal Fusion Surgery in Osteoporotic Patients. World neurosurgery Chaudhary, N., Lee, J. S., Wu, J. Y., Tharin, S. 2016

    Abstract

    Osteoporosis is defined as a bone mineral density (BMD) less than 2.5 standard deviations below the mean BMD at peak bone mass, or the presence of a fragility fracture. In the setting of osteoporosis, early hardware loosening is thought to cause decreased spinal fusion rates. The two mainstays of osteoporosis treatment are bisphosphonates and Teriparatide. Teriparatide, a form of synthetic parathyroid hormone (PTH), is an anabolic agent that increases osteoblast activity and, thereby, bone mass. Preclinical studies in animal models show that Teriparatide increases spinal fusion rates. Early clinical studies show that teriparatide both increases spinal fusion rates and decreases hardware loosening in the setting of postmenopausal osteoporosis. Ongoing additional trials will help formulate preoperative screening recommendations, determine the optimal duration of pre- and post-operative Teriparatide treatment, and investigate its utility in men.

    View details for DOI 10.1016/j.wneu.2016.11.135

    View details for PubMedID 27923758

  • Calcinosis is associated with digital ulcers and osteoporosis in patients with systemic sclerosis: A Scleroderma Clinical Trials Consortium study SEMINARS IN ARTHRITIS AND RHEUMATISM Valenzuela, A., Baron, M., Herrick, A. L., Proudman, S., Stevens, W., Rodriguez-Reyna, T. S., Vacca, A., Medsger, T. A., Hinchcliff, M., Hsu, V., Wu, J. Y., Fiorentino, D., Chung, L. 2016; 46 (3): 344-349

    Abstract

    We sought to identify the clinical factors associated with calcinosis in an international multicenter collaborative effort with the Scleroderma Clinical Trials Consortium (SCTC).This is a retrospective cohort study of 5218 patients with systemic sclerosis (SSc). Logistic regression was used to obtain odds ratios (OR) relating calcinosis to various clinical features in multivariate analyses.A total of 1290 patients (24.7%) had calcinosis. In univariate analyses, patients with calcinosis were older than patients without calcinosis, more likely to be female, and had longer disease duration from the first non-Raynaud phenomenon symptom. Patients with calcinosis were more likely to have digital ulcers, telangiectasias, acro-osteolysis, cardiac disease, pulmonary hypertension, gastrointestinal involvement, arthritis, and osteoporosis, but less likely to have muscle disease. Anti-Scl-70, RNA-polymerase-III, and U1-RNP autoantibodies were significantly less common in patients with calcinosis, while anticentromere (ACA), anti-PM/Scl, and anticardiolipin antibodies were more frequent. In multivariate analysis, the strongest associations with calcinosis were digital ulcers (OR = 3.9; 95% CI: 2.7-5.5; p < 0.0001) and osteoporosis (OR = 4.2; 95% CI: 2.3-7.9; p < 0.0001).One quarter of patients with SSc have calcinosis at some time during their illness. Our data confirm a strong association of calcinosis with digital ulcers, and support a novel association with osteoporosis.

    View details for DOI 10.1016/j.semarthrit.2016.05.008

    View details for Web of Science ID 000390979200012

    View details for PubMedID 27371996

  • SIKs control osteocyte responses to parathyroid hormone NATURE COMMUNICATIONS Wein, M. N., Liang, Y., Goransson, O., Sundberg, T. B., Wang, J., Williams, E. A., O'Meara, M. J., Govea, N., Beqo, B., Nishimori, S., Nagano, K., Brooks, D. J., Martins, J. S., Corbin, B., Anselmo, A., Sadreyev, R., Wu, J. Y., Sakamoto, K., Foretz, M., Xavier, R. J., Baron, R., Bouxsein, M. L., Gardella, T. J., Divieti-Pajevic, P., Gray, N. S., Kronenberg, H. M. 2016; 7

    Abstract

    Parathyroid hormone (PTH) activates receptors on osteocytes to orchestrate bone formation and resorption. Here we show that PTH inhibition of SOST (sclerostin), a WNT antagonist, requires HDAC4 and HDAC5, whereas PTH stimulation of RANKL, a stimulator of bone resorption, requires CRTC2. Salt inducible kinases (SIKs) control subcellular localization of HDAC4/5 and CRTC2. PTH regulates both HDAC4/5 and CRTC2 localization via phosphorylation and inhibition of SIK2. Like PTH, new small molecule SIK inhibitors cause decreased phosphorylation and increased nuclear translocation of HDAC4/5 and CRTC2. SIK inhibition mimics many of the effects of PTH in osteocytes as assessed by RNA-seq in cultured osteocytes and following in vivo administration. Once daily treatment with the small molecule SIK inhibitor YKL-05-099 increases bone formation and bone mass. Therefore, a major arm of PTH signalling in osteocytes involves SIK inhibition, and small molecule SIK inhibitors may be applied therapeutically to mimic skeletal effects of PTH.

    View details for DOI 10.1038/ncomms13176

    View details for Web of Science ID 000385617700001

    View details for PubMedID 27759007

    View details for PubMedCentralID PMC5075806

  • Induction of LIFR confers a dormancy phenotype in breast cancer cells disseminated to the, bone marrow NATURE CELL BIOLOGY Johnson, R. W., Fingers, E. C., Olcina, M. M., Vilalta, M., Aguilera, T., Miao, Y., Merkel, A. R., Johnson, J. R., Sterling, J. A., Wu, J. Y., Giaccia, A. J. 2016; 18 (10): 1078-1089

    Abstract

    Breast cancer cells frequently home to the bone marrow, where they may enter a dormant state before forming a bone metastasis. Several members of the interleukin-6 (IL-6) cytokine family are implicated in breast cancer bone colonization, but the role for the IL-6 cytokine leukaemia inhibitory factor (LIF) in this process is unknown. We tested the hypothesis that LIF provides a pro-dormancy signal to breast cancer cells in the bone. In breast cancer patients, LIF receptor (LIFR) levels are lower with bone metastases and are significantly and inversely correlated with patient outcome and hypoxia gene activity. Hypoxia also reduces the LIFR:STAT3:SOCS3 signalling pathway in breast cancer cells. Loss of the LIFR or STAT3 enables otherwise dormant breast cancer cells to downregulate dormancy-, quiescence- and cancer stem cell-associated genes, and to proliferate in and specifically colonize the bone, suggesting that LIFR:STAT3 signalling confers a dormancy phenotype in breast cancer cells disseminated to bone.

    View details for DOI 10.1038/ncb3408

    View details for Web of Science ID 000384961700007

    View details for PubMedID 27642788

  • Bone marrow hematopoietic niches Osteoimmunology: Interactions of the Immune and Skeletal Systems, 2nd Edition Wu, J. Y., Kronenberg, H. M. Academic Press. 2016: 103–119
  • Pluripotent Stem Cells and Skeletal Regeneration-Promise and Potential CURRENT OSTEOPOROSIS REPORTS Wu, J. Y. 2015; 13 (5): 342-350
  • RAR gamma is a negative regulator of osteoclastogenesis JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY Green, A. C., Poulton, I. J., Vrahnas, C., Haeusler, K. D., Walkley, C. R., Wu, J. Y., Martin, T. J., Gillespie, M. T., Chandraratna, R. A., Quinn, J. M., Sims, N. A., Purton, L. E. 2015; 150: 46-53
  • Activation of the Wnt/Planar Cell Polarity Pathway Is Required for Pericyte Recruitment during Pulmonary Angiogenesis. American journal of pathology Yuan, K., Orcholski, M. E., Panaroni, C., Shuffle, E. M., Huang, N. F., Jiang, X., Tian, W., Vladar, E. K., Wang, L., Nicolls, M. R., Wu, J. Y., de Jesus Perez, V. A. 2015; 185 (1): 69-84

    Abstract

    Pericytes are perivascular cells localized to capillaries that promote vessel maturation, and their absence can contribute to vessel loss. Whether impaired endothelial-pericyte interaction contributes to small vessel loss in pulmonary arterial hypertension (PAH) is unclear. Using 3G5-specific, immunoglobulin G-coated magnetic beads, we isolated pericytes from the lungs of healthy subjects and PAH patients, followed by lineage validation. PAH pericytes seeded with healthy pulmonary microvascular endothelial cells failed to associate with endothelial tubes, resulting in smaller vascular networks compared to those with healthy pericytes. After the demonstration of abnormal polarization toward endothelium via live-imaging and wound-healing studies, we screened PAH pericytes for abnormalities in the Wnt/planar cell polarity (PCP) pathway, which has been shown to regulate cell motility and polarity in the pulmonary vasculature. PAH pericytes had reduced expression of frizzled 7 (Fzd7) and cdc42, genes crucial for Wnt/PCP activation. With simultaneous knockdown of Fzd7 and cdc42 in healthy pericytes in vitro and in a murine model of angiogenesis, motility and polarization toward pulmonary microvascular endothelial cells were reduced, whereas with restoration of both genes in PAH pericytes, endothelial-pericyte association was improved, with larger vascular networks. These studies suggest that the motility and polarity of pericytes during pulmonary angiogenesis are regulated by Wnt/PCP activation, which can be targeted to prevent vessel loss in PAH.

    View details for DOI 10.1016/j.ajpath.2014.09.013

    View details for PubMedID 25447046

  • Specific bone cells produce DLL4 to generate thymus-seeding progenitors from bone marrow. The Journal of experimental medicine 2015

    Abstract

    Production of the cells that ultimately populate the thymus to generate α/β T cells has been controversial, and their molecular drivers remain undefined. Here, we report that specific deletion of bone-producing osteocalcin (Ocn)-expressing cells in vivo markedly reduces T-competent progenitors and thymus-homing receptor expression among bone marrow hematopoietic cells. Decreased intrathymic T cell precursors and decreased generation of mature T cells occurred despite normal thymic function. The Notch ligand DLL4 is abundantly expressed on bone marrow Ocn(+) cells, and selective depletion of DLL4 from these cells recapitulated the thymopoietic abnormality. These data indicate that specific mesenchymal cells in bone marrow provide key molecular drivers enforcing thymus-seeding progenitor generation and thereby directly link skeletal biology to the production of T cell-based adaptive immunity.

    View details for DOI 10.1084/jem.20141843

    View details for PubMedID 25918341

  • The PTH-G alpha(s)-Protein Kinase A Cascade Controls alpha NAC Localization To Regulate Bone Mass MOLECULAR AND CELLULAR BIOLOGY Pellicelli, M., Miller, J. A., Arabian, A., Gauthier, C., Akhouayri, O., Wu, J. Y., Kronenberg, H. M., St-Arnaud, R. 2014; 34 (9): 1622-1633

    Abstract

    The binding of PTH to its receptor induces Gαs-dependent cAMP accumulation to turn on effector kinases, including protein kinase A (PKA). The phenotype of mice with osteoblasts specifically deficient for Gαs is mimicked by a mutation leading to cytoplasmic retention of the transcriptional coregulator αNAC, suggesting that Gαs and αNAC form part of a common genetic pathway. We show that treatment of osteoblasts with PTH(1-34) or the PKA-selective activator 6Bnz-cAMP lead to translocation of αNAC to the nucleus. αNAC was phosphorylated by PKA at serine 99 in vitro. Phospho-S99-αNAC accumulated in osteoblasts exposed to PTH(1-34) or 6Bnz-cAMP but not in treated cells expressing dominant negative PKA. Nuclear accumulation was abrogated by an S99A mutation but enhanced by a phosphomimetic residue (S99D). ChIP analysis showed that PTH(1-34) or 6Bnz-cAMP treatment leads to accumulation of αNAC at the Osteocalcin (Ocn) promoter. Altered gene dosage for Gαs and αNAC in compound heterozygous mice results in reduced bone mass, increased numbers of osteocytes, and enhanced expression of Sost. Our results show that αNAC is a substrate of PKA following PTH signaling. This enhances αNAC translocation to the nucleus and leads to its accumulation at target promoters to regulate transcription and affect bone mass.

    View details for DOI 10.1128/MCB.01434-13

    View details for Web of Science ID 000334316300007

    View details for PubMedID 24550008

  • Mesenchymal progenitors and the osteoblast lineage in bone marrow hematopoietic niches. Current osteoporosis reports Panaroni, C., Tzeng, Y., Saeed, H., Wu, J. Y. 2014; 12 (1): 22-32

    Abstract

    The bone marrow cavity is essential for the proper development of the hematopoietic system. In the last few decades, it has become clear that mesenchymal stem/progenitor cells as well as cells of the osteoblast lineage, besides maintaining bone homeostasis, are also fundamental regulators of bone marrow hematopoiesis. Several studies have demonstrated the direct involvement of mesenchymal and osteoblast lineage cells in the maintenance and regulation of supportive microenvironments necessary for quiescence, self-renewal and differentiation of hematopoietic stem cells. In addition, specific niches have also been identified within the bone marrow for maturing hematopoietic cells. Here we will review recent findings that have highlighted the roles of mesenchymal progenitors and cells of the osteoblast lineage in regulating distinct stages of hematopoiesis.

    View details for DOI 10.1007/s11914-014-0190-7

    View details for PubMedID 24477415

  • Differential regulation of myeloid leukemias by the bone marrow microenvironment. Nature medicine Krause, D. S., Fulzele, K., Catic, A., Sun, C. C., Dombkowski, D., Hurley, M. P., Lezeau, S., Attar, E., Wu, J. Y., Lin, H. Y., Divieti-Pajevic, P., Hasserjian, R. P., Schipani, E., Van Etten, R. A., Scadden, D. T. 2013; 19 (11): 1513-1517

    Abstract

    Like their normal hematopoietic stem cell counterparts, leukemia stem cells (LSCs) in chronic myelogenous leukemia (CML) and acute myeloid leukemia (AML) are presumed to reside in specific niches in the bone marrow microenvironment (BMM) and may be the cause of relapse following chemotherapy. Targeting the niche is a new strategy to eliminate persistent and drug-resistant LSCs. CD44 (refs. 3,4) and interleukin-6 (ref. 5) have been implicated previously in the LSC niche. Transforming growth factor-β1 (TGF-β1) is released during bone remodeling and plays a part in maintenance of CML LSCs, but a role for TGF-β1 from the BMM has not been defined. Here, we show that alteration of the BMM by osteoblastic cell-specific activation of the parathyroid hormone (PTH) receptor attenuates BCR-ABL1 oncogene-induced CML-like myeloproliferative neoplasia (MPN) but enhances MLL-AF9 oncogene-induced AML in mouse transplantation models, possibly through opposing effects of increased TGF-β1 on the respective LSCs. PTH treatment caused a 15-fold decrease in LSCs in wild-type mice with CML-like MPN and reduced engraftment of immune-deficient mice with primary human CML cells. These results demonstrate that LSC niches in CML and AML are distinct and suggest that modulation of the BMM by PTH may be a feasible strategy to reduce LSCs, a prerequisite for the cure of CML.

    View details for DOI 10.1038/nm.3364

    View details for PubMedID 24162813

  • Interactions between B lymphocytes and the osteoblast lineage in bone marrow. Calcified tissue international Panaroni, C., Wu, J. Y. 2013; 93 (3): 261-268

    Abstract

    The regulatory effects of the immune system on the skeleton during homeostasis and activation have been appreciated for years. In the past decade it has become evident that bone tissue can also regulate immune cell development. In the bone marrow, the differentiation of hematopoietic progenitors requires specific microenvironments, called "niches," provided by various subsets of stromal cells, many of which are of mesenchymal origin. Among these stromal cell populations, cells of the osteoblast lineage serve a supportive function in the maintenance of normal hematopoiesis, and B lymphopoiesis in particular. Within the osteoblast lineage, distinct differentiation stages exert differential regulatory effects on hematopoietic development. In this review we will highlight the critical role of osteoblast progenitors in the perivascular B lymphocyte niche.

    View details for DOI 10.1007/s00223-013-9753-3

    View details for PubMedID 23839529

  • Myelopoiesis is regulated by osteocytes through Gsa-dependent signaling. Blood Fulzele, K., Krause, D. S., Panaroni, C., Saini, V., Barry, K. J., Liu, X., Lotinun, S., Baron, R., Bonewald, L., Feng, J. Q., Chen, M., Weinstein, L. S., Wu, J. Y., Kronenberg, H. M., Scadden, D. T., Divieti Pajevic, P. 2013; 121 (6): 930-939

    Abstract

    Hematopoietic progenitors are regulated in their respective niches by cells of the bone marrow microenvironment. The bone marrow microenvironment is composed of a variety of cell types, and the relative contribution of each of these cells for hematopoietic lineage maintenance has remained largely unclear. Osteocytes, the most abundant yet least understood cells in bone, are thought to initiate adaptive bone remodeling responses via osteoblasts and osteoclasts. Here we report that these cells regulate hematopoiesis, constraining myelopoiesis through a Gsα-mediated mechanism that affects G-CSF production. Mice lacking Gsα in osteocytes showed a dramatic increase in myeloid cells in bone marrow, spleen, and peripheral blood. This hematopoietic phenomenon was neither intrinsic to the hematopoietic cells nor dependent on osteoblasts but was a consequence of an altered bone marrow microenvironment imposed by Gsα deficiency in osteocytes. Conditioned media from osteocyte-enriched bone explants significantly increased myeloid colony formation in vitro, which was blocked by G-CSF–neutralizing antibody, indicating a critical role of osteocyte-derived G-CSF in the myeloid expansion.

    View details for DOI 10.1182/blood-2012-06-437160

    View details for PubMedID 23160461

  • Development of the skeleton Osteoporosis, 4th Edition Provot, S., Schipani, E., Wu, J. Y., Kronenberg, H. M. Academic Press. 2013: 97–126
  • G(s)alpha enhances commitment of mesenchymal progenitors to the osteoblast lineage but restrains osteoblast differentiation in mice JOURNAL OF CLINICAL INVESTIGATION Wu, J. Y., Aarnisalo, P., Bastepe, M., Sinha, P., Fulzele, K., Selig, M. K., Chen, M., Poulton, I. J., Purton, L. E., Sims, N. A., Weinstein, L. S., Kronenberg, H. M. 2011; 121 (9): 3492-3504

    Abstract

    The heterotrimeric G protein subunit Gsα stimulates cAMP-dependent signaling downstream of G protein-coupled receptors. In this study, we set out to determine the role of Gsα signaling in cells of the early osteoblast lineage in vivo by conditionally deleting Gsα from osterix-expressing cells. This led to severe osteoporosis with fractures at birth, a phenotype that was found to be the consequence of impaired bone formation rather than increased resorption. Osteoblast number was markedly decreased and osteogenic differentiation was accelerated, resulting in the formation of woven bone. Rapid differentiation of mature osteoblasts into matrix-embedded osteocytes likely contributed to depletion of the osteoblast pool. In addition, the number of committed osteoblast progenitors was diminished in both bone marrow stromal cells (BMSCs) and calvarial cells of mutant mice. In the absence of Gsα, expression of sclerostin and dickkopf1 (Dkk1), inhibitors of canonical Wnt signaling, was markedly increased; this was accompanied by reduced Wnt signaling in the osteoblast lineage. In summary, we have shown that Gsα regulates bone formation by at least two distinct mechanisms: facilitating the commitment of mesenchymal progenitors to the osteoblast lineage in association with enhanced Wnt signaling; and restraining the differentiation of committed osteoblasts to enable production of bone of optimal mass, quality, and strength.

    View details for DOI 10.1172/JCI46406

    View details for Web of Science ID 000294753700017

    View details for PubMedID 21804192

  • Potent constitutive cyclic AMP-generating activity of XL alpha s implicates this imprinted GNAS product in the pathogenesis of McCune-Albright Syndrome and fibrous dysplasia of bone BONE Mariot, V., Wu, J. Y., Aydin, C., Mantovani, G., Mahon, M. J., Linglart, A., Bastepe, M. 2011; 48 (2): 312-320

    Abstract

    Patients with McCune-Albright syndrome (MAS), characterized primarily by hyperpigmented skin lesions, precocious puberty, and fibrous dyslasia of bone, carry postzygotic heterozygous mutations of GNAS causing constitutive cAMP signaling. GNAS encodes the α-subunit of the stimulatory G protein (Gsα), as well as a large variant (XLαs) derived from the paternal allele. The mutations causing MAS affect both GNAS products, but whether XLαs, like Gsα, can be involved in the pathogenesis remains unknown. Here, we investigated biopsy samples from four previously reported and eight new patients with MAS. Activating mutations of GNAS (Arg201 with respect to the amino acid sequence of Gsα) were present in all the previously reported and five of the new cases. The mutation was detected within the paternally expressed XLαs transcript in five and the maternally expressed NESP55 transcript in four cases. Tissues carrying paternal mutations appeared to have higher XLαs mRNA levels than maternal mutations. The human XLαs mutant analogous to Gsα-R201H (XLαs-R543H) showed markedly higher basal cAMP accumulation than wild-type XLαs in transfected cells. Wild-type XLαs demonstrated higher basal and isoproterenol-induced cAMP signaling than Gsα and co-purified with Gβ1γ2 in transduced cells. XLαs mRNA was measurable in mouse calvarial cells, with its level being significantly higher in undifferentiated cells than those expressing preosteoblastic markers osterix and alkaline phosphatase. XLαs mRNA was also expressed in murine bone marrow stromal cells and preosteoblastic MC3T3-E1 cells. Our findings are consistent with the possibility that constitutive XLαs activity adds to the molecular pathogenesis of MAS and fibrous dysplasia of bone.

    View details for DOI 10.1016/j.bone.2010.09.032

    View details for Web of Science ID 000286543700019

    View details for PubMedID 20887824

  • The role of bone cells in establishing the hematopoietic stem cell niche Osteoimmunology: Interactions of the Immune and Skeletal Systems Wu, J. Y., Kronenberg, H. M. 2011: 81–99
  • Clarifying the contributions of distinct mesenchymal populations in supporting hematopoiesis [editorial] IBMS BoneKEy Wu, J. Y. 2010; 7: 369-372
  • Role of the Osteoblast Lineage in the Bone Marrow Hematopoietic Niches JOURNAL OF BONE AND MINERAL RESEARCH Wu, J. Y., Scadden, D. T., Kronenberg, H. M. 2009; 24 (5): 759-764

    View details for DOI 10.1359/JBMR.090225

    View details for Web of Science ID 000265550000001

    View details for PubMedID 19257832

  • Osteoblastic regulation of B lymphopoiesis is mediated by G(s)alpha-dependent signaling pathways PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA Wu, J. Y., Purton, L. E., Rodda, S. J., Chen, M., Weinstein, L. S., McMahon, A. P., Scadden, D. T., Kronenberg, H. M. 2008; 105 (44): 16976-16981

    Abstract

    Osteoblasts play an increasingly recognized role in supporting hematopoietic development and recently have been implicated in the regulation of B lymphopoiesis. Here we demonstrate that the heterotrimeric G protein alpha subunit G(s)alpha is required in cells of the osteoblast lineage for normal postnatal B lymphocyte production. Deletion of G(s)alpha early in the osteoblast lineage results in a 59% decrease in the percentage of B cell precursors in the bone marrow. Analysis of peripheral blood from mutant mice revealed a 67% decrease in the number of circulating B lymphocytes by 10 days of age. Strikingly, other mature hematopoietic lineages are not decreased significantly. Mice lacking G(s)alpha in cells of the osteoblast lineage exhibit a reduction in pro-B and pre-B cells. Furthermore, interleukin (IL)-7 expression is attenuated in G(s)alpha-deficient osteoblasts, and exogenous IL-7 is able to restore B cell precursor populations in the bone marrow of mutant mice. Finally, the defect in B lymphopoiesis can be rescued by transplantation into a WT microenvironment. These findings confirm that osteoblasts are an important component of the B lymphocyte niche and demonstrate in vivo that G(s)alpha-dependent signaling pathways in cells of the osteoblast lineage extrinsically regulate bone marrow B lymphopoiesis, at least partially in an IL-7-dependent manner.

    View details for DOI 10.1073/pnas.0802898105

    View details for Web of Science ID 000260913800034

    View details for PubMedID 18957542

  • Development of the Skeleton Osteoporosis, 3rd Edition Provot, S., Schipani, E., Wu, J. Y., Kronenberg, H. M. Academic Press. 2008: 241–269
  • Spermatogenesis and the regulation of Ca2+-calmodulin-dependent protein kinase IV localization are not dependent on calspermin MOLECULAR AND CELLULAR BIOLOGY Wu, J. Y., Ribar, T. J., Means, A. R. 2001; 21 (17): 6066-6070

    Abstract

    Calspermin and Ca(2+)-calmodulin-dependent protein kinase IV (CaMKIV) are two proteins encoded by the Camk4 gene. CaMKIV is found in multiple tissues, including brain, thymus, and testis, while calspermin is restricted to the testis. In the mouse testis, both proteins are expressed within elongating spermatids. We have recently shown that deletion of CaMKIV has no effect on calspermin expression but does impair spermiogenesis by disrupting the exchange of sperm basic nuclear proteins. The function of calspermin within the testis is unclear, although it has been speculated to play a role in binding and sequestering calmodulin during the development of the germ cell. To investigate the contribution of calspermin to spermatogenesis, we have used Cre/lox technology to specifically delete calspermin, while leaving kinase expression intact. We unexpectedly found that calspermin is not required for male fertility. We further demonstrate that CaMKIV expression and localization are unaffected by the absence of calspermin and that calspermin does not colocalize to the nuclear matrix with CaMKIV.

    View details for Web of Science ID 000170349900034

    View details for PubMedID 11486043

  • Female fertility is reduced in mice lacking Ca2+ calmodulin-dependent protein kinase IV ENDOCRINOLOGY Wu, J. Y., Gonzalez-Robayna, I. J., Richards, J. S., Means, A. R. 2000; 141 (12): 4777-4783

    Abstract

    Ca2+/calmodulin-dependent protein kinase IV (CaMKIV) is a serine/threonine protein kinase with limited tissue distribution. CaMKIV is highly expressed in the testis, where it is found in transcriptionally inactive elongating spermatids. We have recently generated mice deficient in CaMKIV. In the absence of CaMKIV, the exchange of sperm nuclear basic proteins in male spermatids is impaired, resulting in male infertility secondary to defective spermiogenesis. The involvement of CaMKIV in female fertility has not been addressed. Here we report that female fertility is markedly reduced in CaMKIV-deficient mice due to impaired follicular development and ovulation. CaMKIV is expressed in the ovary, where it is localized in granulosa cells. We further find that in cultured granulosa cells, CaMKIV expression and subcellular localization are hormonally regulated. As granulosa cells differentiate, CaMKIV levels decrease and the kinase translocates from the nucleus into the cytoplasm. Our results demonstrate a critical role for CaMKIV in female reproduction and point to a potential function in granulosa cell differentiation.

    View details for Web of Science ID 000165360900056

    View details for PubMedID 11108293

  • Spermiogenesis and exchange of basic nuclear proteins are impaired in male germ cells lacking Camk4 NATURE GENETICS Wu, J. Y., Ribar, T. J., Cummings, D. E., Burton, K. A., McKnight, G. S., Means, A. R. 2000; 25 (4): 448-452

    Abstract

    Ca2+/calmodulin-dependent protein kinase IV (Camk4; also known as CaMKIV), a multifunctional serine/threonine protein kinase with limited tissue distribution, has been implicated in transcriptional regulation in lymphocytes, neurons and male germ cells. In the mouse testis, however, Camk4 is expressed in spermatids and associated with chromatin and nuclear matrix. Elongating spermatids are not transcriptionally active, raising the possibility that Camk4 has a novel function in male germ cells. To investigate the role of Camk4 in spermatogenesis, we have generated mice with a targeted deletion of the gene Camk4. Male Camk4-/- mice are infertile with impairment of spermiogenesis in late elongating spermatids. The sequential deposition of sperm basic nuclear proteins on chromatin is disrupted, with a specific loss of protamine-2 and prolonged retention of transition protein-2 (Tnp2) in step-15 spermatids. Protamine-2 is phosphorylated by Camk4 in vitro, implicating a connection between Camk4 signalling and the exchange of basic nuclear proteins in mammalian male germ cells. Defects in protamine-2 have been identified in sperm of infertile men, suggesting that our results may have clinical implications for the understanding of human male infertility.

    View details for Web of Science ID 000088615000024

    View details for PubMedID 10932193

  • Ca2+/calmodulin-dependent protein kinase IV is expressed in spermatids and targeted to chromatin and the nuclear matrix JOURNAL OF BIOLOGICAL CHEMISTRY Wu, J. Y., Means, A. R. 2000; 275 (11): 7994-7999

    Abstract

    Ca(2+)/calmodulin-dependent protein kinase IV and calspermin are two proteins encoded by the Camk4 gene. Both are highly expressed in the testis, where in situ hybridization studies in rat testes have demonstrated that CaMKIV mRNA is localized to pachytene spermatocytes, while calspermin mRNA is restricted to spermatids. We have examined the expression patterns of both CaMKIV and calspermin in mouse testis and unexpectedly find that CaMKIV is expressed in spermatogonia and spermatids but excluded from spermatocytes, while calspermin is found only in spermatids. CaMKIV and calspermin expression in the testis are stage-dependent and appear to be coordinately regulated. In germ cells, we find that CaMKIV is associated with the chromatin. We further demonstrate that a fraction of CaMKIV in spermatids is hyperphosphorylated and specifically localized to the nuclear matrix. These novel findings may implicate CaMKIV in chromatin remodeling during nuclear condensation of spermatids.

    View details for Web of Science ID 000085913300078

    View details for PubMedID 10713118

  • Pharmacology Crashing the boards: a user friendly study guide for the USMLE step 1 Wu, J. Y. Lippincott Williams and Wilkins. 1999; 2: 31–47